Skip to main content
. Author manuscript; available in PMC: 2015 Jan 6.
Published in final edited form as: Pediatr Blood Cancer. 2013 Oct 11;61(4):647–652. doi: 10.1002/pbc.24822

Table II. Outcome for All Patients According to the Survivin-2B/ΔEx2 Ratio.

Survivin-2B/ΔEx2 <1 (n = 68) Survivin-2B/ΔEx2 ≥ 1 (n = 22)


N % ± 2SE% N % ± 2SE% P-value
5-year OS from study entry 68 60 ± 12 22 36 ± 21 0.011
5-year EFS from study entry 68 53 ± 12 22 23 ± 18 0.001
5-year OS from end of course 1 59 65 ± 13 10 60 ± 31 0.665
5-year DFS from end of course 1 59 57 ± 13 10 40 ± 31 0.323
5-year RR from end of course 1 59 31 ± 12 10 60 ± 31 0.061
5-year TRM from end of course 1 59 12 ± 9 10 0 ± 0 0.263
5-year OS from end of course 2 47 70 ± 14 12 50 ± 29 0.134
5-year DFS from end of course 2 47 61 ± 14 12 33 ± 27 0.066
5-year RR from end of course 2 47 32 ± 14 12 58 ± 28 0.056
5-year TRM from end of course 2 47 6 ±7 12 8 ± 16 0.834

OS, overall survival; EFS, event-free survival; DFS, disease-free survival; RR, relapse rate; TRM, treatment-related mortality; SE, standard error.